翰森制药集团宣布,其创新药物HS-10,568注射液用于治疗成人慢性肾脏病患者继发性甲状旁腺功能亢进的新药上市申请,已获得中国国家药品监督管理局的正式受理。此举标志着该药物在中国商业化进程中的关键一步,有望为相关患者群体提供新的治疗选择。
翰森制药集团宣布,其创新药物HS-10,568注射液用于治疗成人慢性肾脏病患者继发性甲状旁腺功能亢进的新药上市申请,已获得中国国家药品监督管理局的正式受理。此举标志着该药物在中国商业化进程中的关键一步,有望为相关患者群体提供新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.